Taverner D, Bickford L, Draper M
Clinical and Experimental Pharmacology, University of Adelaide, Frome RD, Adelaide, South Australia, Australia, 5006.
Cochrane Database Syst Rev. 2000(2):CD001953. doi: 10.1002/14651858.CD001953.
The common cold is a major and recurrent cause of morbidity, affecting children and adults two or more times each year. Nasal congestion is its commonest symptom, and many therapies are marketed for its relief. There is no meta-analysis of controlled clinical trials on the effects of nasal decongestants for the common cold.
To assess the efficacy of nasal decongestants at reducing the symptom of nasal congestion in adults and children with the common cold and to identify possible adverse effects associated with their use.
MEDLINE, EMBASE and Current Contents were searched up to May 1999. Searching the Cochrane Acute Respiratory Infections Group's trials register, following the review citation trail from other references and contacting known principal investigators and pharmaceutical companies was also done.
Randomised, placebo controlled trials of single-active oral and topical nasal decongestants in adults and children suffering from the common cold.
Data were independently extracted by two reviewers (DT and LB). All outcomes variables were continuous. Subjective outcomes were normalised to a common scale and a weighted mean difference (WMD) was calculated. A standardised mean difference (SMD) was calculated for the objective outcomes.
Four studies in adults, but none in children, fitted all inclusion criteria. There was a significant 13% decrease in subjective symptoms after decongestant compared with placebo. This was supported by a significant decrease in nasal airways resistance. Repeated doses of nasal decongestant were not significantly better than placebo at relieving symptoms of nasal congestion.
REVIEWER'S CONCLUSIONS: A single dose of nasal decongestant in the common cold is moderately effective for the short term relief of congestion in adults, while there is no evidence available to show benefit after repeated use over several days. These medications are not recommended for use in young children with the common cold.
普通感冒是发病的主要且反复出现的原因,每年影响儿童和成人达两次或更多次。鼻塞是其最常见的症状,市场上有许多用于缓解鼻塞的疗法。目前尚无关于减充血剂对普通感冒疗效的对照临床试验的荟萃分析。
评估减充血剂对减轻普通感冒成人和儿童鼻塞症状的疗效,并确定其使用可能产生的不良反应。
检索了截至1999年5月的MEDLINE、EMBASE和《现刊目次》。还检索了Cochrane急性呼吸道感染小组的试验注册库,追踪其他参考文献的综述引用线索,并联系了知名的主要研究者和制药公司。
针对患有普通感冒的成人和儿童,采用单活性口服和局部鼻腔减充血剂的随机、安慰剂对照试验。
由两名评价员(DT和LB)独立提取数据。所有结局变量均为连续性变量。主观结局进行标准化处理,使其处于同一量表,并计算加权平均差(WMD)。客观结局计算标准化平均差(SMD)。
有四项针对成人的研究符合所有纳入标准,但没有针对儿童的研究。与安慰剂相比,使用减充血剂后主观症状显著降低了13%。鼻气道阻力的显著降低也支持了这一结果。重复使用鼻腔减充血剂在缓解鼻塞症状方面并不比安慰剂显著更好。
对于普通感冒,单剂量鼻腔减充血剂对成人短期缓解鼻塞有中度疗效,而没有证据表明连续几天重复使用有好处。不建议在患普通感冒的幼儿中使用这些药物。